Skip to content

Prevention of Diseases Induced by Chlamydia Trachomatis

Prevention of Diseases Induced by Chlamydia Trachomatis

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02904811
Acronym
i-PREDICT
Enrollment
1092
Registered
2016-09-19
Start date
2017-01-10
Completion date
2022-11-15
Last updated
2023-03-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Genital Chlamydia Trachomatis Infection

Keywords

Chlamydia trachomatis, Pelvic inflammatory disease

Brief summary

The main objective of the study is to determine whether early screening and treating young women (\<25 years of age) for genital Chlamydia Trachomatis (Ct) infection reduces the cumulative incidence of pelvic inflammatory disease (PID) over 24 months. As secondary objectives, the study aims * To determine the baseline prevalence and the incidence of Ct infection; * To improve knowledge on natural history of Ct infection in young women such as the rate and timing of progression to PID (at the beginning of the infection, at the end, throughout the course of infection), as well as the incidence of reinfections with Ct; * To investigate the relation between host immuno-genetic factors and the clearance, persistence and development of late complications (PID) as an explanation for the inter-individual heterogeneity in the susceptibility to and course of Ct infection.

Detailed description

In this research project, the study aims to assess a screening strategy (early screening and treatment of Ct genital infection in young women to prevent complications) that may be implemented in the future if proved efficient 7 centers are involved in the enrollment (university health services), and 4 centers will participate in the study within the frame of the follow-up and final visit (hospital gynaecology departments). Participants included will have to perform 4 self-taken vaginal samples linked to four online corresponding questionnaires, at different timeframes 6-month apart to each other (M0, M6, M12, M18). The first sampling (M0) will be performed at the university health service, this self-taken sampling could also be performed at home later in case of menstruation; the others (M6, M12, M18) will be performed at home (or at the university if problem of sampling kits receiving at home). Participants will be randomly assigned to one of the two following arms: * in the non-intervention arm, participants will follow current guidelines of Ct screening (i.e. opportunistic screening only in STI clinics for women aged less than 25 years old), and their samples will be tested for Ct at M18 by the NRC; * in the intervention arm, analyses for Ct will be carried out immediately by the NRC. A final visit with a hospital gynecologist is planned for all participants between M18 and M24 and aims at providing an extensive clinical examination to seek for potential signs of pelvic inflammatory disease and to treat participants if needed. Based on all data collected on the electronic platform through questionnaires from the different visits, independent experts blinded on chlamydia status will assess PID status of all participants (no PID, probable PID, confirmed PID). The duration of enrollment is planned for 36 months. The duration of follow-up for each patient is 18 months to 24 months.

Interventions

OTHERTesting for Ct infection immediately

Self-taken vaginal samples will be immediately tested for Ct infection at the National Reference Centre (CNR) at University of Bordeaux, using a commercially available CE marketed real-time PCR assay.

OTHERTesting for Ct infection at the end of the study

Self-taken vaginal samples will be tested for Ct infection at the end of the study (M18).

Sponsors

National Reference Center (NRC) for Chlamydia infections, UMR1181
CollaboratorUNKNOWN
Assistance Publique - Hôpitaux de Paris
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 24 Years
Healthy volunteers
Yes

Inclusion criteria

* female students visiting the preventive medical centers of universities or the Ct screening test centers who participate in the study; * participate in or will participate in the i-Share cohort; * aged between 18 to 24 years, * had prior sexual relations, * written informed consent signed, * affiliated to the social security bodies.

Exclusion criteria

* Known pregnancy.

Design outcomes

Primary

MeasureTime frameDescription
Cumulative incidenceAt 24 monthsCumulative incidence of first PID

Secondary

MeasureTime frameDescription
Duration of Ct infectionUp to 24 months
Proportion of Ct infection progressing to PIDUp to 24 months
Incidence of first Ct infectionUp to 24 monthsIncidence of first Ct infection for negative participants at baseline
Proportion of spontaneous resolution of Ct infectionsUp to 24 monthsProportion of spontaneous resolution of Ct infections
Incidence of reinfectionsUp to 24 monthsIncidence of reinfections
Time of Ct infection progressing to PIDUp to 24 months

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 8, 2026